Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome associated with infection by the newly emergent coronavirus SARS-CoV-2. SARS-CoV-2 was first identified in late 2019 and rapidly spread throughout the world, earning classification as a pandemic by the World Health Organization (WHO) in early 2020. In the United States, tests for COVID-19 viral infection have been hampered by lack of testing supplies, lack of personal protection equipment (i.e. masks and gloves), and the need of healthcare workers to focus on the sickest individuals. The inability to provide large scale testing has had a number of untoward effects on the pandemic, at a public policy level as well as on an individual level. A lag in testing capacity globally has made it difficult to make informed decisions about public health and safety, as communities implement unprecedented measures to prevent the spread of the virus.
One unusual and challenging aspect of COVID-19 is that up to 60% of individuals who carry the virus and are contagious, are asymptomatic. These individuals may be caregivers, food service workers, bus drivers or family members. Implementation of routine testing of individuals in public-facing jobs will be important to limit the spread of disease and protect our most vulnerable citizens.
ResourcePath was originally founded to develop niche molecular testing and liquid biopsies for pediatric cancers and other underserved populations and diseases. Over the past few years, funding from NIH has helped us build a dedicated and highly skilled team of molecular technologists, and equipment designed to detect miniscule amounts of cancerous tumor DNA in blood. This technology has helped to accelerate early diagnosis and monitoring the effectiveness of chemotherapy in cancer with a simple blood test.
Then the COVID-19 pandemic arrived.
In late March, as the pandemic worsened in Virginia and elsewhere, we decided to adapt our expertise and equipment to help fill the gap in testing availability, and provide testing for COVID-19 active infection. We use real-time RT-qPCR to detect three different gene targets in SARS-CoV-2 RNA. Importantly, we have validated our test performance in saliva and have found it to be as reliable and accurate as other sample types. While we also accept nasal swabs and nasopharyngeal swabs, saliva eliminates the need for a collection swab, which are becoming increasingly difficult to obtain through the supply chain.
We are a small and flexible company and are happy to discuss how we can meet your testing needs. If you are a physician, pharmacist, business owner or involved in county government COVID response, please see our additional information for providers.
More Information and Helpful Links:
Johns Hopkins U.S. County Level COVID-19 Tracking Map
Coronavirus disease 2019 (COVID-19) is a virus (more specifically, a coronavirus) identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
Effective May 15, Governor Northam issued Executive Order 61 and Order of Public Health Emergency Three, which outlines the Phase One easing of certain temporary restrictions due to novel coronavirus (COVID-19), with the exception of several localities, including the Northern Virginia Region, the City of Richmond, and Accomack County, which have requested a delay.
Find information about respiratory illness caused by novel coronavirus disease COVID-19.